Zim Laboratories Allocates Employee Stock Options, Increasing Share Capital to Over ₹53 Crore
Zim Laboratories Limited announced the allotment of Equity Shares under its employee stock option scheme, following a resolution passed by its Board of Directors. The move increased the company's paid-up equity share capital significantly.The Board approved the allotment of 1,09,451 fully paid up Equity Shares to eligible employees of the Company and its Subsidiary. These shares were allotted upon the exercise of options vested under the 'ZIM Laboratories Employee Stock Option Scheme (ESOS 2023)'. The event occurred on July 13, 2026, at 11:56 a.m.
The allotment resulted in an increase in the company's paid-up equity share capital. Previously, the capital stood at Rs. 53,54,90,370/-, consisting of 5,35,49,037 equity shares of face value Rs. 10/- each.
Following this transaction, the company's paid-up equity share capital rose to Rs. 53,65,84,880/-. This new total figure covers a total of 5,36,58,488 equity shares of face value Rs. 10/- each.
Key details regarding the ESOP allotment and financial realization are as follows:
| Particulars | Details |
|---|---|
| Type of Securities Proposed to be Issued | Equity Shares |
| Type of Issue | ESOP Allotment |
| Total Number of Securities Proposed to be Listed | 1,09,451 Equity shares |
| Money Realized by Exercise of Options | Rs. 84,71,507.40/- |
The scheme used for the issuance is named 'ZIM Laboratories Employee Stock Option Scheme 2023'. The shares issued on July 13, 2026, have a par value of Rs. 10/- per share. After this issue, the total number of shares issued by the company stands at 5,36,58,488, resulting in the total issued share capital of Rs. 53,65,84,880/-. The allotted shares are identical to existing equity shares and rank pari-passu with them.
ZIMLAB Stock Price Movement
Shares of ZIMLAB are shedding value as of 12:30 PM, dropping 0.24% in live trading and currently holding at ₹113.35. Trading volume stands at 15,132 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.